Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models.
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Inhibition of tumor angiogenesis by blockading the vascular endothelial growth factor (VEGF) signaling pathway is a promising therapeutic strategy for thyroid cancer. Lenvatinib mesilate (lenvatinib) is a potent inhibitor of VEGF receptors (VEGFR1-3) and other prooncogenic and prooncogenic receptor tyrosine kinases, including fibroblast growth factor receptors (FGFR1-4), platelet derived growth factor receptor α (PDGFRα), KIT, and RET. We examined the antitumor activity of lenvatinib against human thyroid cancer xenograft models in nude mice. Orally administered lenvatinib showed significant antitumor activity in 5 differentiated thyroid cancer (DTC), 5 anaplastic thyroid cancer (ATC), and 1 medullary thyroid cancer (MTC) xenograft models. Lenvatinib also showed antiangiogenesis activity against 5 DTC and 5 ATC xenografts, while lenvatinib showed in vitro antiproliferative activity against only 2 of 11 thyroid cancer cell lines: that is, RO82-W-1 and TT cells. Western blot analysis showed that cultured RO82-W-1 cells overexpressed FGFR1 and that lenvatinib inhibited the phosphorylation of FGFR1 and its downstream effector FRS2. Lenvatinib also inhibited the phosphorylation of RET with the activated mutation C634W in TT cells. These data demonstrate that lenvatinib provides antitumor activity mainly via angiogenesis inhibition but also inhibits FGFR and RET signaling pathway in preclinical human thyroid cancer models.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Lenvatinib is an oral TKI of VEGFRs, FGFRs, PDGFRα, KIT, and RET.”
From Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma (2024) · cites this paper as [22]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Folkman, J., & Klagsbrun, M. (1987) · Science · doi:10.1126/science.2432664 · Cited by 3,491
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A
Mulligan, L. M., Kwok, J. B. J., Healey, C. S., Elsdon, M. J., Eng, C., Gardner, E., Love, D. R., Mole, S. E., Moore, J. K., Papi, L., et al. (1993) · Nature · doi:10.1038/363458a0 · Cited by 1,966
Induction of angiogenesis during the transition from hyperplasia to neoplasia
Folkman, J., Watson, K., Ingber, D., & Hanahan, D. (1989) · Nature · doi:10.1038/339058a0 · Cited by 1,879
Brose, M. S., Nutting, C. M., Jarzab, B., Elisei, R., Siena, S., Bastholt, L., de la Fouchardiere, C., Pacini, F., Paschke, R., Shong, Y. K., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60421-9 · Cited by 1,663
Wells, S. A., Robinson, B. G., Gagel, R. F., Dralle, H., Fagin, J. A., Santoro, M., Baudin, E., Elisei, R., Jarzab, B., Vasselli, J. R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.5040 · Cited by 1,559
Molecular pathogenesis and mechanisms of thyroid cancer
Xing, M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3431 · Cited by 1,426
Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC
Donis-Keller, H., Dou, S., Chi, D., Carlson, K. M., Toshima, K., Lairmore, T. C., Howe, J. R., Moley, J. F., Goodfellow, P., & Wells, S. A. (1993) · Human Molecular Genetics · doi:10.1093/hmg/2.7.851 · Cited by 1,303
Research works printed but not linked: 1
- 2002, Cancer Research, 62, 5749
Cited by
Items 201–300 of 505
Fazio, N., Cella, C. A., Re, M. D., Laffi, A., Rubino, M., Zagami, P., & Spada, F. (2019) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1700951 · Cited by 20
Pembrolizumab in endometrial cancer: Where we stand now (Review)
Aravantinou‐Fatorou, A., Andrikopoulou, Α., Liontos, M., Fiste, O., Georgakopoulou, V., Dimopoulos, M. A., Gavriatopoulou, M., & Zagouri, F. (2021) · Oncology Letters · doi:10.3892/ol.2021.13082 · Cited by 20
Zheng, X., Wang, J., Ye, T., Tang, W., Pan, X., Wang, S., & Liu, J. (2023) · Endocrine · doi:10.1007/s12020-023-03390-y · Cited by 20
Chen, Y., Luo, Z., Ren, Z., Shen, L., Li, R., Chen, L., & Du, C. (2022) · The Journal of Chemical Thermodynamics · doi:10.1016/j.jct.2022.106922 · Cited by 20
Revilla, G., Qtaish, N. A., Caruana, P., Sainz-Ramos, M., López-Méndez, T. B., Rodriguez, F., Páez-Espinosa, V., Li, C., Vallverdú, N. F., Edwards, M., et al. (2023) · Biomolecules · doi:10.3390/biom13111647 · Cited by 19
Thyroid Cancer and COVID-19: Prospects for Therapeutic Approaches and Drug Development
Qu, N., Hui, Z., Shen, Z., Kan, C., Hou, N., Sun, X., & Han, F. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.873027 · Cited by 19
Yang, Y., Tang, H. J., Mai, C., Zhang, X., Kuang, J., & Tang, Y. (2023) · Letters in Drug Design & Discovery · doi:10.2174/1570180820666230601113529 · Cited by 19
Okusaka, T., Ikeda, K., Kudo, M., Finn, R. S., Qin, S., Han, K., Cheng, A., Piscaglia, F., Kobayashi, M., Sung, M. W., et al. (2021) · Journal of Gastroenterology · doi:10.1007/s00535-021-01785-0 · Cited by 19
Lenvatinib: A narrative drug review
Goel, A., & Singla, A. (2021) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_151_21 · Cited by 19
Suzuki, K., Iwai, H., Utsunomiya, K., Kono, Y., Kobayashi, Y., Bui, D. V., Sawada, S., Yun, Y., Mitani, A., Kondo, N., et al. (2020) · Experimental Cell Research · doi:10.1016/j.yexcr.2020.112390 · Cited by 19
Destructive Thyroiditis Induced by Lenvatinib in Three Patients with Hepatocellular Carcinoma
Hirooka, M., Ochi, H., Hiraoka, A., Koizumi, Y., Matsuura, B., Joko, K., Michitaka, K., Abe, M., & Hiasa, Y. (2018) · Internal Medicine · doi:10.2169/internalmedicine.1874-18 · Cited by 19
Liu, J., Yang, L., Song, W., Li, J., & Yi, P. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05342-5 · Cited by 18
Huang, Y., Du, Z., Kan, A., He, M., Li, H., Lai, Z., Wen, D., Huang, L., Li, Q., Xu, L., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1260191 · Cited by 18
Tori, M., & Shimo, T. (2018) · BMC Cancer · doi:10.1186/s12885-018-4612-2 · Cited by 18
Elia, G., Ferrari, S. M., Ragusa, F., Paparo, S. R., Mazzi, V., Ulisse, S., Benvenga, S., Antonelli, A., & Fallahi, P. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2030704 · Cited by 18
Suzuki, N., Tajiri, K., Futsukaichi, Y., Tanaka, S., Murayama, A., Entani, T., Kobayashi, S., Takahashi, K., Fujii, T., Imura, J., et al. (2020) · Case Reports in Gastroenterology · doi:10.1159/000505774 · Cited by 18
Motomura, K., Kuwano, A., Tanaka, K., Koga, Y., Masumoto, A., & Yada, M. (2023) · Cancers · doi:10.3390/cancers15174345 · Cited by 17
Ding, Y., Wang, S., Qiu, Z., Zhu, C., Wang, Y., Zhao, S., Qiu, W., Wang, K., Lv, J., & Qi, W. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1284937 · Cited by 17
Persano, M., Gardini, A. C., Tada, T., Suda, G., Shimose, S., Kudo, M., Rossari, F., Yoo, C., Cheon, J., Finkelmeier, F., et al. (2024) · Oncology · doi:10.1159/000541018 · Cited by 17
Xu, Y., Fu, S., Ye, M., Huang, S., Li, D., & Wu, J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.919069 · Cited by 17
Novel treatment options for anaplastic thyroid cancer
Fallahi, P., Ruffilli, I., Elia, G., Ragusa, F., Ulisse, S., Baldini, E., Miccoli, M., Materazzi, G., Antonelli, A., & Ferrari, S. M. (2017) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2017.1340155 · Cited by 17
Duan, Y., Zhang, H., Tan, T., Ye, W., Yin, K.-L., Yu, Y., Kang, M., Yang, J., & Liao, R. (2023) · BioScience Trends · doi:10.5582/bst.2023.01275 · Cited by 17
Ning, Z., Xie, L., Xia, Y., Hua, Y., Shi, W., Lin, J., Xu, L., & Meng, Z. (2023) · British Journal of Radiology · doi:10.1259/bjr.20230079 · Cited by 17
Neoadjuvant Lenvatinib in Advanced Unresectable Medullary Thyroid Carcinoma: A Case Report
Golingan, H., Hunis, B., Golding, A. C., Bimston, D. N., & Harrell, R. M. (2019) · AACE Clinical Case Reports · doi:10.4158/accr-2019-0365 · Cited by 17
Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma
Tomonari, T., Sato, Y., Tanaka, H., Mitsuhashi, T., Hirao, A., Tanaka, T., Taniguchi, T., Okamoto, K., Sogabe, M., Miyamoto, H., et al. (2021) · JGH Open · doi:10.1002/jgh3.12663 · Cited by 17
Self-citationSun, P., Li, Z., Yan, Z., Wang, Z., Zheng, P., Wang, M., Xu, C., Liu, Z., Zhang, J., Wu, H., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-12680-1 · Cited by 17
Lenvatinib and its Use in the Treatment of Unresectable Hepatocellular Carcinoma
Baxter, M. A., Glen, H., & Evans, T. R. (2018) · Future Oncology · doi:10.2217/fon-2017-0689 · Cited by 17
Date, E., Okamoto, K., Fumita, S., & Kaneda, H. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0522-4 · Cited by 17
Self-citationThe Tumor Microenvironment in Hepatocellular Carcinoma
Nagaoka, K., Tanaka, Y., & Hino, O. (2022) · Interdisciplinary cancer research · doi:10.1007/16833_2022_66 · Cited by 16
Shalata, W., Iraqi, M., Bhattacharya, B., Fuchs, V., Roisman, L. C., Cohen, A. Y., Massalha, I., Yakobson, A., Prasad, M., Elkabets, M., et al. (2021) · Cancers · doi:10.3390/cancers13143630 · Cited by 16
Tchekmedyian, V. (2021) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2021.05.011 · Cited by 16
Lenvatinib for the treatment of kidney cancer
Študentová, H., Vitásková, D., & Melichar, B. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1470506 · Cited by 16
Clinical pharmacology and drug-drug interactions of lenvatinib in thyroid cancer
Fogli, S., Gianfilippo, G., Cucchiara, F., Re, M. D., Valerio, L., Elisei, R., & Danesi, R. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103366 · Cited by 16
Liu, J., Li, J.-J., Yan, S., Zhang, G.-N., & Yi, P. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1074793 · Cited by 15
Hatanaka, T., Kakizaki, S., Hiraoka, A., Tada, T., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.6726 · Cited by 15
Dubbelman, A.-C., Nijenhuis, C. M., Jansen, R. S., Rosing, H., Mizuo, H., Kawaguchi, S., Critchley, D. J. P., Shumaker, R., Schellens, J. H. M., & Beijnen, J. H. (2016) · Investigational New Drugs · doi:10.1007/s10637-016-0342-y · Cited by 15
Honda, S., Saito, Y., Sawada, K., Hasebe, T., Nakajima, S., & Okumura, T. (2019) · Internal Medicine · doi:10.2169/internalmedicine.3806-19 · Cited by 15
Zhai, J., Liu, J., Fu, Z., Bai, S., Li, X., Qu, Z., Sun, Y., Ge, R., & Xue, F. (2022) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-22-404 · Cited by 15
Kim, H. S., Kim, S., Jung, E., Lee, K., Lee, J., Kang, H., Joo, Y., Lim, S. C., & Yoon, T. (2021) · Oncology Reports · doi:10.3892/or.2021.7969 · Cited by 15
Zhao, B., Zhou, Y., Cheng, N., Zheng, X., Chen, G., Qi, X., Zhang, X., Wang, F., Zhuang, Q., Assaraf, Y. G., et al. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03386-8 · Cited by 15
Treatment options after first-line immunotherapy in metastatic NSCLC
Santos, E. S. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1738930 · Cited by 14
Zhang, Y., Zhang, H., Xu, H., Wang, Y., Feng, L., & Yi, F. (2024) · World Journal of Surgical Oncology · doi:10.1186/s12957-024-03396-4 · Cited by 14
Liu, J., Xia, S., Zhang, B., Mohammed, D. M., Yang, X., Zhu, Y., & Jiang, X. (2024) · Discover Oncology · doi:10.1007/s12672-024-01110-0 · Cited by 14
Smith, E. A., Belote, R. L., Cruz, N. M., Moustafa, T. E., Becker, C. A., Jiang, A., Alizada, S., Prokofyeva, A., Chan, T. Y., Seasor, T. A., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03234-1 · Cited by 14
Ning, Z., Yang, L., Yan, X., Wang, D., Hua, Y., Shi, W., Lin, J., & Meng, Z. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612828666220113161712 · Cited by 14
Long, F., Chen, S., Li, R., Lin, Y., Han, J., Guo, J., Chen, Y., Li, C., & Song, P. (2023) · Medical Oncology · doi:10.1007/s12032-023-02012-x · Cited by 14
Liu, J., Wei, S., Yang, L., Yu, J., Duan, Y., & Yi, P. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05231-x · Cited by 13
Antiangiogenic drugs: Chemosensitizers for combination cancer therapy
Donnini, S., Filippelli, A., Ciccone, V., Spini, A., Ristori, E., Ziche, M., & Morbidelli, L. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90190-1.00008-1 · Cited by 13
Lin, Z., Zou, X., Hu, X., Huang, D., Chen, Y., Lin, J., Li, X., & Zhang, J. (2024) · Scientific Reports · doi:10.1038/s41598-024-75102-z · Cited by 13
Is Autophagy Targeting a Valid Adjuvant Strategy in Conjunction with Tyrosine Kinase Inhibitors?
Elshazly, A. M., Xu, J., Melhem, N. Y., Abdulnaby, A., Elzahed, A. A., Saleh, T., & Gewirtz, D. A. (2024) · Cancers · doi:10.3390/cancers16172989 · Cited by 13
Mishall, K. M., Beadnell, T. C., Kuenzi, B. M., Klimczak, D. M., Superti‐Furga, G., Rix, U., & Schweppe, R. E. (2017) · Oncotarget · doi:10.18632/oncotarget.20488 · Cited by 13
Enomoto, K., Hirayama, S., Kumashiro, N., Jing, X., Kimura, T., Tamagawa, S., Matsuzaki, I., Murata, S.-I., & Hotomi, M. (2021) · Cancers · doi:10.3390/cancers13040862 · Cited by 13
Self-citationMatsui, J. (2016) · Global Journal of Cancer Therapy · doi:10.17352/gjct.000009 · Cited by 13
Self-citationLenvatinib Therapy for the Treatment of Patients with Advanced Renal Cell Carcinoma
Glen, H. (2016) · Future Oncology · doi:10.2217/fon-2016-0215 · Cited by 13
Sueshige, Y., Shiraiwa, K., Honda, K., Tanaka, R., Saito, T., Tokoro, M., Iwao, M., Endo, M., Arakawa, M., Tatsuta, R., et al. (2021) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000872 · Cited by 13
Juthani, R., Malalur, P. G., Manne, A., & Mittra, A. (2025) · Cancers · doi:10.3390/cancers17091572 · Cited by 12
Wang, G., Zhang, W., Luan, X., Wang, Z., Liu, J., Xu, X., Zhang, J., Xu, B., Lu, S., Wang, R., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1151967 · Cited by 12
Considerations for individualized first-line systemic treatment in advanced hepatocellular carcinoma
Peeters, F., & Dekervel, J. (2023) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2023.102365 · Cited by 12
Current Translational and Clinical Challenges in Advanced Hepatocellular Carcinoma
Frizziero, M., McNamara, M. G., Lamarca, Á., Pihlak, R., Kurup, R., & Hubner, R. A. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200422143847 · Cited by 12
Piscaglia, F., Ikeda, K., Cheng, A., Kudo, M., Ikeda, M., Breder, V. V., Ryoo, B., Mody, K., Ren, M., Ramji, Z., et al. (2024) · Cancer · doi:10.1002/cncr.35185 · Cited by 12
Wu, J., Zeng, J., Wang, H., Huo, Z., Hou, X., & He, D. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1244341 · Cited by 12
de la Fouchardière, C., Ghuzlan, A. A., Bardet, S., Borget, I., Borson‐Chazot, F., Cao, C. D., Godbert, Y., Leenhardt, L., Zerdoud, S., & Leboulleux, S. (2019) · Bulletin du Cancer · doi:10.1016/j.bulcan.2019.04.012 · Cited by 12
Lenvatinib in the management of metastatic renal cell carcinoma: a promising combination therapy?
Lisi, D. D., Giorgi, U. D., Lolli, C., Schepisi, G., Conteduca, V., Menna, C., Tonini, G., Santini, D., & Farolfi, A. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1455826 · Cited by 12
Kotani, K., Enomoto, M., Okada, M., Yoshida, K., Motoyama, H., Fujii, H., Hagihara, A., Uchida‐Kobayashi, S., Morikawa, H., Murakami, Y., et al. (2019) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-019-00983-x · Cited by 12
Furuse, J., Izumi, N., Motomura, K., Inaba, Y., Katamura, Y., Kondo, Y., Yabushita, K., Motoyoshi, K., & Kudo, M. (2023) · Drugs - Real World Outcomes · doi:10.1007/s40801-022-00348-w · Cited by 12
Terashima, T., Yamashita, T., Takata, N., Takeda, Y., Kido, H., Iida, N., Kitahara, M., Shimakami, T., Takatori, H., Arai, K., et al. (2020) · Hepatology Research · doi:10.1111/hepr.13588 · Cited by 11
Suzuki, K., Iwai, H., Utsunomiya, K., Kono, Y., Watabe, T., Kobayashi, Y., Bui, D. V., Sawada, S., Yun, Y., Mitani, A., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179872 · Cited by 11
Efficacy of lenvatinib in treating thyroid cancer
Krajewska, J., Kukulska, A., & Jarząb, B. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1206078 · Cited by 11
Paragliola, R. M., Corsello, A., Gatto, V. D., Papi, G., Pontecorvi, A., & Corsello, S. M. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1674280 · Cited by 11
Legros, L., Pascale, A., Guettier, C., Eftekhari, P., Merabet, Y. B., Stang, M., Bossevot, R., Goldschmidt, E., Ulusakarya, A., Morisset, S., et al. (2023) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-023-04519-6 · Cited by 11
Lai, X., Wan, Q., Jiao, S., Sun, X.-C., Hu, J., & Peng, H. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2251398 · Cited by 11
Inhibition of IRAK1/4 enhances the antitumor effect of lenvatinib in anaplastic thyroid cancer cells
Kawamura, Y., Saijo, K., Imai, H., & Ishioka, C. (2021) · Cancer Science · doi:10.1111/cas.15095 · Cited by 11
Sun, L., Qi, J., Ding, L., Wang, Z., Ji, G., & Zhang, P. (2024) · Scientific Reports · doi:10.1038/s41598-024-79069-9 · Cited by 10
Kudo, M., Finn, R. S., Ikeda, M., Sung, M. W., Baron, A. D., Okusaka, T., Kobayashi, M., Kumada, H., Kaneko, S., Pracht, M., et al. (2023) · Liver Cancer · doi:10.1159/000535154 · Cited by 10
McGonagle, E. R., & Nucera, C. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00468 · Cited by 10
Yuan, F., Tang, Y., Liang, H., Cao, M., Ren, Y., Li, Y., Yang, G., Zhong, Z., Xiong, Z., He, Z., et al. (2025) · Genomics · doi:10.1016/j.ygeno.2025.110999 · Cited by 10
Huang, J., Liu, B., Li, Y., Li, X., Ding, L., & Wang, N.-Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1204486 · Cited by 10
Lenvatinib and pembrolizumab in advanced gastric cancer
Cascinu, S. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30336-3 · Cited by 10
Tanabe, N., Saeki, I., Yamaoka, K., Kawaoka, T., Tomonari, T., Tani, J., Terashima, T., Kawamura, Y., Oka, S., Takayama, T., et al. (2025) · Anticancer Research · doi:10.21873/anticanres.17499 · Cited by 10
Mukozu, T., Nagai, H., Matsui, D., Mohri, K., Watanabe, G., Yoshimine, N., Amanuma, M., Kobayashi, K., Ogino, Y., Matsukiyo, Y., et al. (2021) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-021-04359-2 · Cited by 10
Gaspar, N., Campbell-Hewson, Q., Huang, J., Okpara, C. E., & Bautista, F. (2021) · Future Oncology · doi:10.2217/fon-2021-0743 · Cited by 9
Lei, Y., Liang, X., Zhu, H., Wang, J., Zhang, X., Duan, S., & Liang, W. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1586914 · Cited by 9
Wang, Z., Song, S., Zhang, L., Yang, T., Yao, W., & Liang, B. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1474442 · Cited by 9
Fuchs, V., Kian, W., Lichtenberg, R. S., Cooper, J. M., Remilah, A. A., Levin, D., Peled, N., & Roisman, L. C. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-021-01116-4 · Cited by 9
Thymic epithelial tumors: what’s new and what’s next?
Imbimbo, M., Salfi, G., Borgeaud, M., Ottaviano, M., Froesch, P., Bouchaab, H., Cafarotti, S., & Addeo, A. (2025) · ESMO rare cancers. · doi:10.1016/j.esmorc.2025.100024 · Cited by 9
Scarini, J. F., Lavareze, L., de Lima‐Souza, R. A., Emerick, C., Gonçalves, M. T., Maciel, T. F., Vieira, G. D. S., Kimura, T. D. C., de Sá, R. S., Aquino, I. G., et al. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103863 · Cited by 9
Self-citationKobayashi, T., Iwama, S., Yamagami, A., Izuchi, T., Suzuki, K. A. O., Otake, K., Yasuda, Y., Ando, M., Onoue, T., Miyata, T., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03733-2 · Cited by 9
Guo, T., Liu, P., Yang, J., Wu, P., Chen, B., Liu, Z., & Li, Z. (2019) · Journal of Cancer · doi:10.7150/jca.32828 · Cited by 9
Wu, H., Gu, X., Li, J., Wang, M., Li, Y., Yuan, L., Wang, J., & Ma, E. (2019) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2019.107527 · Cited by 9
Yu, R., Wang, M., Zhu, X., Sun, Z., Jiang, A., & Huixin, Y. (2018) · Oncology Letters · doi:10.3892/ol.2018.9428 · Cited by 9
Adashek, J. J., Breunig, J. J., Posadas, E. M., Bhowmick, N. A., Ellis, L., Freedland, S. J., Kim, H. L., Figlin, R. A., & Gong, J. (2022) · Drugs · doi:10.1007/s40265-022-01683-6 · Cited by 8
Shin, H. P., & Lee, M. (2025) · Medicina · doi:10.3390/medicina61122164 · Cited by 8
Advancements in Hepatocellular Carcinoma: Potential Preclinical Drugs and their Future
Baytaş, S. N., & Butt, N.-U.-H. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612829666221216114350 · Cited by 8
Decraecker, M., Toulouse, C., & Blanc, J. (2021) · Cancers · doi:10.3390/cancers13246310 · Cited by 8
Sho, T., Morikawa, K., Kubo, A., Tokuchi, Y., Kitagataya, T., Yamada, R., Shigesawa, T., Kimura, M., Nakai, M., Suda, G., et al. (2021) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v13.i12.2076 · Cited by 8
Namba, M., Kawaoka, T., Aikata, H., Kodama, K., Uchikawa, S., Ohya, K., Morio, K., Fujino, H., Nakahara, T., Murakami, E., et al. (2019) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-019-00938-2 · Cited by 8
Self-citationSato, A., Imai, Y., Uchiya, H., Uchida, Y., Nakazawa, M., Sugawara, K., Nakayama, N., & Mochida, S. (2022) · Internal Medicine · doi:10.2169/internalmedicine.8733-21 · Cited by 8
State of the Art in 3D Culture Models Applied to Thyroid Cancer
Prete, A., Matrone, A., & Plebani, R. (2024) · Medicina · doi:10.3390/medicina60040520 · Cited by 7
Systemic Treatment for Older Patients with Unresectable Hepatocellular Carcinoma
Cammarota, A., D’Alessio, A., Pressiani, T., Rimassa, L., & Personeni, N. (2021) · Drugs & Aging · doi:10.1007/s40266-021-00871-5 · Cited by 7
Advances in pharmacotherapeutics for hepatocellular carcinoma
Cerrito, L., Santopaolo, F., Monti, F., Pompili, M., Gasbarrini, A., & Ponziani, F. R. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1892074 · Cited by 7
Metadata
- Authors
- Tohyama, O., Matsui, J., Kodama, K., Hata-Sugi, N., Kimura, T., Okamoto, K., Minoshima, Y., Iwata, M., & Funahashi, Y.
- Affiliations
- Eisai (Japan) (JP)
- Eisai (United States) (US)
- Corresponding author
- Funahashi, Yasuhiro
- ORCID
- Venue
- Journal of Thyroid Research
- Publisher
- Wiley
- Published
- 2014
- Volume
- 2014
- Pages
- 1-13
- ISSN
- 2042-0072 (ISSN-L)
- 2090-8067
- PMC
- PMC4177084
- OpenAlex
- W2094109552
- Cited by
- 475
- References
- 50
- Citations by year
- 2026: 18 · 2025: 22 · 2024: 49 · 2023: 69 · 2022: 57 · 2021: 69 · 2020: 52 · 2019: 53 · 2018: 38 · 2017: 17 · 2016: 18 · 2015: 12 · 2014: 1
- FWCI
- 13.15
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Journal of Thyroid Research (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Keywords
- lenvatinib, thyroid cancer, angiogenesis inhibition, VEGF receptor signaling, FGFR1, RET, receptor tyrosine kinase inhibitors, anaplastic thyroid carcinoma, medullary thyroid carcinoma, differentiated thyroid cancer, xenograft models, antiproliferative activity, FRS2, KIT, PDGFRA
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.